How big is the metabolic dysfunction-associated steatohepatitis (mash) treatment market today, and what are its future growth expectations?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size has grown exponentially in recent years. It will grow from $2.00 billion in 2024 to $2.60 billion in 2025 at a compound annual growth rate (CAGR) of 30.0%. The growth in the historic period can be attributed to the rising incidence of non-alcoholic steatohepatitis, modern dietary habits, eating high in processed foods, sedentary lifestyles, and increasing prevalence of metabolic.
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market size is expected to see exponential growth in the next few years. It will grow to $7.38 billion in 2029 at a compound annual growth rate (CAGR) of 29.8%. The growth in the forecast period can be attributed to the increasing prevalence of obesity and obesity-related diseases, early intervention, reimbursement mechanisms, insurance coverage, and growing awareness of liver diseases. Major trends in the forecast period include an increase in technological advancements, pipeline development, strategic collaborations and partnerships, personalized medicine and precision therapeutics, and investment in clinical trials and research.
Get Your Free Sample of The Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
What have been the primary factors driving the metabolic dysfunction-associated steatohepatitis (mash) treatment market’s growth?
The increasing prevalence of obesity is expected to propel the growth of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market going forward. Obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact overall health, typically measured by a body mass index (BMI) of 30 or higher. The prevalence of obesity is rising globally, driven by sedentary lifestyles, unhealthy diets, and metabolic risk factors. Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment in obesity focuses on addressing insulin resistance, reducing liver fat, and improving metabolic health through lifestyle changes and targeted therapies. For instance, in March 2023, according to the World Heart Foundation, a Switzerland-based non-government global cardiovascular community, Currently, approximately 2.3 billion adults and children worldwide are obese or overweight, and with the ongoing obesity trend, this number is projected to reach 2.7 billion by 2025. Therefore, the increasing prevalence of obesity is driving growth in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
What are the key segments within the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market covered in this report is segmented –
1) By Treatment: By Drug, By Therapy
2) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists, Other Drugs (Anti-Inflammatory Agents)
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Order your report now for swift delivery
Which key players are shaping the metabolic dysfunction-associated steatohepatitis (mash) treatment market?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lily and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Celerion, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, 89 Bio, Biosynth, DiogenX, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals
How will emerging trends drive the metabolic dysfunction-associated steatohepatitis (mash) treatment market throughout the forecast period?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are focusing on developing innovative products such as liver fibrosis treatment solutions to provide the treatment option for patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. Liver fibrosis treatment solutions focus on addressing the underlying causes of liver damage through lifestyle modifications, antiviral medications, and emerging antifibrotic therapies, aiming to halt or reverse the progression of fibrosis and improve liver function. For instance, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that demonstrated efficacy in resolving MASH without worsening fibrosis and improving liver fibrosis in phase 3 clinical trials. This breakthrough offers a non-invasive treatment alternative, eliminating the need for liver biopsies, and significantly improves patient access and outcomes in managing fatty liver disease.
How do regional factors impact the metabolic dysfunction-associated steatohepatitis (mash) treatment market, and which region is the largest contributor?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Report 2025 Offer?
The metabolic dysfunction-associated steatohepatitis (mash) treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Metabolic dysfunction-associated steatohepatitis (MASH) treatment refers to medical and lifestyle interventions aimed at addressing inflammation and liver damage caused by fat accumulation in the liver associated with metabolic dysfunctions like obesity, diabetes, and insulin resistance, focusing on improving liver health and metabolic outcomes.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20876
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
